The Phase 2 REFINE Trial: Ruxolitinib Plus Navitoclax for Myelofibrosis

Naveen Pemmaraju, MD, provides his expert perspective on currently available treatment options in myelofibrosis and data from the REFINE trial on the experimental therapy of ruxolitinib plus navitoclax.